Use of molecular surveillance data to identify clusters of recent and rapid HIV transmission

Similar documents
Detecting HIV transmission clusters to better prioritize prevention efforts

PS : Comprehensive HIV Prevention Programs for Health Departments

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Retaking NPTE

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Overview and Findings from ASTHO s IIS Interstate Data Sharing Meeting

Workforce Data The American Board of Pediatrics

Integrated HIV Statewide Coordinated Statement of Need (SCSN)/Comprehensive Plan Update

Tuberculosis and Travel

Integrated SCSN/Comprehensive Plans and How a Range of Integrated HIV Planning Activities Can Contribute

SASI Analysis of Funds Distributed in the United States By the Centers for Disease Control and Prevention (CDC) Pursuant to PS

Financial Impact of Lung Cancer in West Virginia

The Right Hit. DEVELOPING EFFECTIVE MEDIA STRATEGY AT SYRINGE SERVICES PROGRAMS

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Foreign Educated Physical Therapists

The Affordable Care Act and HIV: What are the Implications?

THREE BIG IMPACT ISSUES

RECOVERY SUPPORT SERVICES IN STATES

2016 COMMUNITY SURVEY

Expedited Partner Therapy (EPT)/Patient Deliver Partner Therapy (PDPT)

A National and Statewide Perspective on the Opioid Crisis

Strategies to Increase Hepatitis C Treatment Within ADAPs

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Foreign Educated PTs and PTAs

Overview of the HHS National Network of Quitlines Initiative

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: License Renewal. License Renewal on Birthdays

SNAP Outreach within Food Banks: A View From The Ground

BY-STATE MENTAL HEALTH SERVICES AND EXPENDITURES IN MEDICAID, 1999

Reducing Disparities in HIV and STDs: Tackling the Challenges in the Southern States and Puerto Rico

African American Women and HIV/AIDS: Confronting the Crisis and Planning for Action

Authorities, Organization, & Key Issues Concerning Federal, State, & Local Public Health Laws

Improving Oral Health:

State of California Department of Justice. Bureau of Narcotic Enforcement

Emerging Issues in Cancer Prevention and Control

Arkansas Prescription Monitoring Program

ANNUAL REPORT EXECUTIVE SUMMARY. The full report is available at DECEMBER 2017

CDC s National Comprehensive Cancer Control Program (NCCCP): 2010 Priorities and New Program Opportunities

State Tobacco Control Programs

Black Women s Access to Health Insurance

HIGHLY PATHOGENIC AVIAN INFLUENZA POLICY UPDATES

Arkansas Prescription Monitoring Program

RAISE Network Webinar Series. Asian Smokers Quitline (ASQ): Promoting Cessation in Our Communities. March 17, :00 pm 2:00 pm PT

Who is paying pharmacists? Network inclusion Standard and simplified processes

Mexico. April August 2009: first wave

Consensus and Collaboration

Dental ER Visits: Evidence of a Failed System. Shelly Gehshan AACDP Conference April 29, 2012

MEDICAID FINANCING OF HPV VACCINE: Access for Low-Income Women

USA National Mental Healthcare Nonprofit Exempt Organization Financial Analysis as of December 14, 2015 January 24, 2016 ANSA-H2

AMERICAN IMMUNIZATION REGISTRY ASSOCIATION A L I S O N C H I, P R O G R A M D I R E C T O R

HEALTH OF WISCONSIN. Children and young adults (ages 1-24) B D REPORT CARD 2016

Different Types of Cancer

Evidence-Based Policymaking: Investing in Programs that Work

Director s Update Brief novel 2009-H1N1. Tuesday 21 JUL EDT Day 95. Week of: Explaining the burden of disease and aligning resources

Improving Cancer Surveillance and Mortality Data for AI/AN Populations

Improving Access to Oral Health Care for Vulnerable and Underserved Populations

Rapidly Growing Molecular Clusters of HIV in Texas. Analise Monterosso, MPH Epidemiologist Molecular HIV Surveillance Coordinator

The drug 3,4-methylenedioxymethamphetamine

Alzheimer s Association Clinical Studies Initiative

The Growing Health and Economic Burden of Older Adult Falls- Recent CDC Research

Voluntary Mental Health Treatment Laws for Minors & Length of Inpatient Stay. Tori Lallemont MPH Thesis: Maternal & Child Health June 6, 2007

The Changing Face of Heroin Use in the US: A Retrospective Analysis of the Past 50 Years 100 Heroin 90 Prescription opioids

a call to states: make alzheimer s a policy priority

Marijuana and driving in the United States: prevalence, risks, and laws

County-Level Analysis of U.S. Licensed Psychologists and Health Indicators

High Impact Prevention: Science, Practice, and the Future of HIV

Using Cancer Registry Data to Estimate the Percentage of Melanomas Attributable to UV Exposure

Using Partner Services Data to Enhance Molecular HIV Surveillance Cluster Analyses

Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index

Report to Congressional Defense Committees

Maternal and Child Health Initiatives in Sickle Cell Disease

San Francisco Medical Monitoring Project (MMP) Maree Kay Parisi Applied Research, Community Health Epidemiology and Surveillance

Shu-Hong Zhu, PhD University of California, San Diego INTRODUCING THE ASIAN SMOKERS QUITLINE (ASQ)

Approach to Cancer Prevention through Policy, Systems, and Environmental Change in the U.S.

Transmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System

AMERICA S OPIOID EPIDEMIC AND ITS EFFECT ON THE NATION S COMMERCIALLY-INSURED POPULATION PUBLISHED JUNE 29, 2017

2018 Perinatal Hepatitis B Summit. Eva Hansson, RN, MSN Perinatal Hepatitis B Prevention Coordinator

Addressing Challenges Together, One Rock at a Time

Christie Eheman, PhD NAACCR 6/2012

Ms. Tramaine Stevenson Director of Program Development and Operations National Council for Behavioral Health

How Often Do Americans Eat Vegetarian Meals? And How Many Adults in the U.S. Are Vegetarian? Posted on May 29, 2015 by The VRG Blog Editor

How to Get Paid for Doing EBD

Women s Health Coverage: Stalled Progress

POLICY BRIEF. State Variability in Access to Hospital-Based Obstetric Services in Rural U.S. Counties. April rhrc.umn.edu. Purpose.

Looking to the Future in HIV Prevention:

Addressing HIV among Hispanic/Latino MSM

UNDER SECRETARY OF DEFENSE 4000 DEFENSE PENTAGON WASHINGTON, D.C

Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995

Reducing Barriers to Risk Appropriate Cancer Genetics Services: Current Strategies

OREGON MEDICAL MARIJUANA PROGRAM STATISTICAL SNAPSHOT JANUARY, 2015 (REVISED 02/26/2015)

Intravitreal Avastin (Bevacizumab)

Drug Overdose Deaths in the United States,

AAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well

Addressing the Substance Abuse Needs of Army National Guard Service Members

Geographic Differences in Event Rates by Model for End-Stage Liver Disease Score

Q1 What is your age?

CHILDHOOD ALLERGIES IN AMERICA

OFFICE OF THE UNDER SECRETARY OF DEFENSE 4000 DEFENSE PENTAGON WASHINGTON, D.C

Moving Forward with the Surgeon General s Call to Action to Prevent Skin Cancer

OREGON MEDICAL MARIJUANA PROGRAM STATISTICAL SNAPSHOT JULY, 2016 (REVISED 09/06/2016)

HEALTH OF WOMEN AND CHILDREN REPORT

LaTanya Runnells, Ph.D Program Manager December 6, 2016

Transcription:

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Use of molecular surveillance data to identify clusters of recent and rapid HIV transmission Alexa Oster, MD Acting Lead, Incidence and Molecular Epidemiology Team Lead, Molecular HIV Surveillance Division of HIV/AIDS Prevention Centers for Disease Control and Prevention March 24, 2017 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention

Background

Identifying active HIV transmission is key to focusing prevention efforts Important to identify growing clusters of recent and rapid transmission in order to intervene to interrupt transmission How do we identify clusters of recent and rapid transmission? HIV case surveillance data can identify trends in diagnoses, but, particularly in high burden areas, these data may obscure growing clusters of active transmission amid other trends Partner services/contact tracing data provide information about transmission networks, however: Not all index patients are interviewed Many partners not named or located Named partners may not represent transmission partners Many jurisdictions do not offer partner services for all new diagnoses

HIV nucleotide sequence data are available and can identify active transmission In the United States, drug resistance testing is recommended for all HIVinfected persons Generates HIV nucleotide sequence data Harnessing these nucleotide sequence data can provide information on transmission relationships and allows to Construct transmission networks that link persons infected with genetically similar HIV variants Identify growing clusters that represent active transmission Focus prevention interventions

Monitoring and preventing HIV The National HIV Surveillance System (NHSS) is the primary source for monitoring HIV infection in the United States Monitors and characterizes trends in HIV to guide public health action at the federal, state, and local levels

Molecular HIV surveillance (MHS): A component of the National HIV Surveillance System HIV nucleotide sequences* Purpose ATGGCATCAATGGCATCATTATCC Assess prevalence of drug resistant strains Describe HIV transmission patterns Antiretroviral use information Identification of clusters and potential outbreaks Cluster Growth Demographics, risk, other case information Monitor genetic diversity of HIV

MHS jurisdictions (N=27), which reported 70% of new HIV diagnoses occurring in 2014 WA MT ND ME San Francisco CA Los Angeles OR NV ID AZ UT WY CO NM SD NE KS OK MN WI IA MO AR IL MI OH IN KY TN PA WV VA NC SC NY VT NH MA RI CT New York City NJ Philadelphia DE MD DC TX LA MS AL GA MHS jurisdiction Non-MHS jurisdiction AK HI Houston P.R. V.I. FL

Collection of nucleotide sequences Persons with HIV Provider orders HIV drug resistance (genotypic) testing Specimen sent to laboratory Resistance report sent to provider Laboratory performs genotypic testing (Sanger) Specimen prepared Viral RNA converted to DNA and amplified Genetic sequence generated and compared with reference Mutations identified and resistance interpreted ATGGCATCA ATGTCATCC HIV sequence reported electronically to health department 27 MHS jurisdictions ATGGCATCA

Using surveillance data to inform prevention

Ways to use molecular HIV data Monitor drug resistance (transmitted and acquired) Examine subtype diversity Understand transmission patterns Corroborate, refute, and understand suspected outbreaks (e.g., Indiana) Identify possible outbreaks and trigger investigation and intervention Monitor outbreaks over time Identify subgroups and networks with active transmission Prioritize prevention efforts

Molecular epidemiology and HIV HIV mutates/evolves over time People living with HIV infection whose viral strains are genetically similar may be more closely related in transmission LA LA LA LA LA LA LA LA LA LA LA LA RA LA LA LA LA LA LA LA LA RA LA LA LA LA YA LA LA LA RA LA MA LA LA YA LA LA LA LA LA LA LA LA LA LA LA LA LA LA LA LA LA LA LA LA RA LA LA LA LA LA LA LA RA LA MA LA LA YA Analysis: compares nucleotide sequences to determine relatedness ACCGGATAACGGTTATCCG ACTGGATAACGGTTATCCG ACCGGATAACGGTTATCCG ACCGAATCACGGAAATCCG

Identifying transmission clusters Compare all pairs of sequences to calculate genetic distance between them Identify pairs of sequences that are very closely related Connect all closely related pairs to identify clusters Link drawn between 2 sequences with close genetic distance A B Image courtesy of Joel Wertheim

Molecular epidemiology and HIV Analysis: compares nucleotide sequences to determine relatedness A B A B Person A infected person B Person B infected person A A C B D Person A infected person C, who infected person B A P ers ons D infected pers ons A and B B We can infer a direct OR indirect epidemiologic link; we cannot infer directionality

Hypothetical molecular cluster identified through sequence analysis A B C D HIV-infected, diagnosed, linked to care HIV-infected, diagnosed but not linked to care HIV-infected, not diagnosed HIV-uninfected, at risk

Interpreting transmission cluster data A transmission cluster includes only those cases that have been diagnosed and have a sequence This represents a subset of the underlying transmission cluster and risk network, which can also include: People who are diagnosed but do not have a sequence included in analysis Diagnosed, but never linked to care Linked to care, but haven t received a genetic resistance test Sequence hasn t been reported to health department People with undiagnosed infection HIV-negative contacts who may be at risk of acquiring HIV

Hypothetical underlying sexual/risk network HIV-infected, diagnosed, linked to care HIV-infected, diagnosed but not linked to care HIV-infected, not diagnosed HIV-uninfected, at risk

Routine CDC analyses to identify active transmission clusters Each quarter, analyze data to identify growing clusters that represent recent, rapid transmission Clusters are prioritized to identify the most concerning clusters nationally Tightly related cases, suggesting rapid transmission At least 5 cases in the cluster identified in most recent 12 month period Initial analysis of data collected through December 2015 1,923 clusters identified, ranging in size from 2-22 cases Of these, 13 met our criteria for rapid growth, with at least 5 cases in most recent 12-month period

Characteristics of 13 high priority clusters Cluster ID Total in cluster Diagnosed in 2015 MSM Drug resistance Virally suppressed Primary census region* A 16 8 94% 3 of 16 69% Northeast B 22 7 91% 17 of 17 68% West C 21 7 86% 20 of 20 57% South D 18 7 83% 0 of 17 67% South E 17 7 94% 15 of 15 94% Northeast F 15 7 93% 15 of 15 73% South G 16 6 100% 14 of 14 63% West H 6 6 100% 0 of 6 67% West I 18 5 94% 0 of 17 78% South J 17 5 94% 0 of 16 82% Multiple, incl. Midwest K 17 5 100% 0 of 16 77% South L 7 5 86% 0 of 6 43% West M 6 5 100% 0 of 6 17% West Most recent viral load was suppressed and occurred in the past 12 months *10 of 13 clusters included cases from more than one surveillance jurisdiction

What steps is CDC taking as we identify high priority clusters? Analyze national surveillance data for cluster and create cluster snapshot Discuss cluster findings with relevant state or local health departments Communicate and collaborate with health departments on Investigation Intervention Quarterly updates provide information on new cases added to previously identified clusters, as well as identifying new clusters meeting the priority criteria for the first time Analysis of 5 quarterly data sets to date have identified approximately 60 total priority clusters As of December 2016, sequences available for >250,000 cases nationally

Cluster investigation is critical Necessary to determine the underlying transmission cluster and risk network Identify persons with diagnosed HIV infection that did not have a sequence included in analysis but are likely cluster cases, and could be contributing to ongoing transmission Identify partners in the network that have not received a diagnosis of HIV infection for Testing or retesting Prevention efforts Determine characteristics of the cluster that could be contributing to ongoing transmission Understanding the cluster allows public health officials to implement public health interventions tailored to the characteristics of the cluster (i.e., geographic, risk, and clinical)

Intervene in entire network as appropriate HIV-infected, diagnosed, linked to care HIV-infected, diagnosed but not linked to care HIV-infected, not diagnosed HIV-uninfected, at risk

Intervening in transmission clusters: Individual-level interventions Characteristic Persons with diagnosed infection who are in care but unsuppressed Persons with diagnosed infection who are not in care Persons with undiagnosed infection HIV-negative persons at risk for acquiring HIV Potential action Promote viral suppression Promote engagement in care, viral suppression Identify (e.g., through partner services or social networks testing project) and link to care Identify (e.g., through partner services or social networks testing project) and offer PrEP

Intervening in transmission clusters: Cluster-level interventions Characteristic Cluster associated with a particular venue Cluster in a remote location Cluster spans multiple jurisdictions Cluster associated with injection drug use Cluster affects a specific population Potential action Targeted outreach for testing and PrEP Educate providers on testing and treatment Collaborate to intervene appropriately Ensure/expand appropriate provision of syringe exchange and substance use treatment Communicate with population at risk about transmission risk

An example cluster

One cluster example NHSS data from December 2015 13 clusters met criteria for rapid growth: at least 5 cases in most recent 12 month period One cluster in TX was particularly concerning As of December 2015 data: 18 members As of June 2016 data: 24 members Primarily young Hispanic/Latino MSM in one metropolitan statistical area CDC and TX Department of State Health Services partnered to investigate Methods: abstraction of medical records and partner services records

Key investigation findings Used partner services data to identify people who might have been part of the transmission cluster but didn t have sequence data Molecular cluster members: n=24 Other people who were sexual or needle sharing partners of molecular cluster cases and their partners: n=87 Abstracted medical records to understand epidemiology of the cluster and identify factors that may have facilitated transmission Despite high levels of risk behaviors and large numbers of partners (many of whom were anonymous partners), no patients had previously taken PrEP Some patients had not been tested using the appropriate algorithm missed opportunity to diagnosed acute infection

Timing of exposure and infectiousness among molecular cluster members

Actions taken to address community factors Drafted a Dear Colleague letter Outlines the rapid growth clusters observed Recommendations for following HIV testing algorithm Recommendations to prescribe PrEP to patients at risk Drafted a health alert Will go out to entire state, medical providers and stakeholders Details the need to use diagnostic algorithm to identify acute HIV cases Recommends HIV genotype testing to identify these clusters 70% increase in prevention funding to San Antonio from DSHS Will fund more testing and additional PrEP clinics Expanding options for notification of anonymous partners via apps and social media sites

A cluster example

Ongoing efforts Guidance for detecting, investigating, and responding to transmission clusters released this month Continuing to expand collection of nucleotide sequence data Developing bioinformatics tools to automate analysis and visualization of molecular data at national and state/local levels Building our knowledge base on optimal approaches to investigate and respond to clusters

Summary Molecular analysis provides an opportunity to identify bursts of recent and rapid transmission The current level of HIV transmission in the United States is likely largely sustained by these types of bursts of transmission Using molecular surveillance data to identify, investigate and intervene recent HIV transmission events can support efforts to improve health outcomes and prevent transmission among these networks May allow us to make progress in reducing new infections in populations that have not yet seen reductions in incidence Cluster data can be a powerful tool to help target the interventions we know are effective (engagement in care, HIV testing, PrEP)

Acknowledgments Local & state HIV surveillance staff Division of HIV/AIDS Prevention Ells Campbell Sharoda Dasgupta Irene Hall Angela Hernandez Anne Marie France Cheryl Ocfemia Nivedha Panneer Neeraja Saduvala Bill Switzer University of California, San Diego: Joel Wertheim TX Department of State Health Services: Analise Monterosso